Study shows GHRH antagonist’s role in AML drug resistance

A new research paper was published in Oncotarget’s Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”

Cognitive behavioral therapy can significantly reduce the burden of fibromyalgia

Patients living with fibromyalgia (FM) – a disease that predominantly affects women and is characterized by chronic pain, fatigue and brain fog – often find

September 21, 2023

FDA approves Lumicell’s breast cancer imaging tool

Dive Brief: The Food and Drug Administration approved Lumicell’s breast cancer imaging tool, the company said Thursday. Lumicell developed the Lumisystem imaging technology to enable surgeons

April 22, 2024

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.